#1 Clinical Trials Search in Europe

Ethinylestradiol

This article explores the use of ethinylestradiol, a synthetic form of estrogen, in clinical trials for oral contraceptives. Ethinylestradiol is commonly combined with progestins to create effective birth control pills. The trials discussed here investigate various aspects of these contraceptive formulations, including their ability to prevent pregnancy, potential drug interactions, and effects on ovulation and hormone levels.

Table of Contents

What is Ethinylestradiol?

Ethinylestradiol is a synthetic form of the hormone estrogen that is commonly used in birth control pills and other hormonal contraceptives. It is often referred to as EE in medical literature[1]. Ethinylestradiol is typically combined with a progestin (a synthetic form of progesterone) to create oral contraceptives that prevent pregnancy.

Uses of Ethinylestradiol

The primary use of ethinylestradiol is for contraception (birth control). It is an essential component of many oral contraceptive pills. However, ethinylestradiol may also be used for other medical purposes, including:

  • Regulating menstrual cycles
  • Treating symptoms of menopause
  • Managing polycystic ovary syndrome (PCOS)
  • Preventing ovulation

In clinical trials, ethinylestradiol has been studied for its effectiveness in inhibiting ovulation, which is crucial for its contraceptive effects[2].

How Ethinylestradiol Works

Ethinylestradiol works by mimicking the effects of natural estrogen in the body. When combined with a progestin in oral contraceptives, it helps prevent pregnancy in several ways:

  1. Inhibiting ovulation: The hormones prevent the ovaries from releasing an egg each month.
  2. Thickening cervical mucus: This makes it harder for sperm to reach the egg.
  3. Changing the lining of the uterus: This makes it less likely for a fertilized egg to implant.

Studies have shown that ethinylestradiol, when combined with progestins like levonorgestrel or gestodene, effectively suppresses ovarian activity and prevents ovulation[2].

Formulations and Combinations

Ethinylestradiol is available in various formulations and combinations, including:

  • Oral tablets: The most common form, often combined with progestins like levonorgestrel or drospirenone[3].
  • Transdermal patches: Deliver ethinylestradiol through the skin[2].
  • Vaginal rings: Release ethinylestradiol and a progestin over time.

Common combinations include:

  • Ethinylestradiol + Levonorgestrel (e.g., Microgynon)
  • Ethinylestradiol + Drospirenone (e.g., Yaz)
  • Ethinylestradiol + Gestodene
  • Ethinylestradiol + Desogestrel (e.g., Marvelon)

Effectiveness

When used correctly, oral contraceptives containing ethinylestradiol are highly effective in preventing pregnancy. Clinical studies have shown that these contraceptives can significantly reduce the risk of ovulation and pregnancy[2].

The effectiveness of ethinylestradiol-containing contraceptives can be influenced by factors such as:

  • Consistent and correct use
  • Interactions with other medications
  • Individual metabolic differences

Potential Side Effects

While ethinylestradiol is generally well-tolerated, it can cause some side effects. Common side effects may include:

  • Nausea
  • Breast tenderness
  • Headaches
  • Mood changes
  • Changes in menstrual bleeding patterns

More serious but rare side effects can include an increased risk of blood clots, especially in women who smoke or have certain health conditions[3].

Drug Interactions

Ethinylestradiol can interact with other medications, potentially affecting its effectiveness or increasing the risk of side effects. Some studies have investigated these interactions, such as:

  • The effect of CP-690,550 on the pharmacokinetics of ethinylestradiol[1]
  • Interactions between ethinylestradiol and JNJ-63623872[3]
  • The impact of BI 201335 on ethinylestradiol levels[4]

It’s important to inform your healthcare provider about all medications you’re taking to avoid potential interactions.

Special Considerations

Some formulations of ethinylestradiol-containing contraceptives may have additional benefits. For example, one study investigated a combination of ethinylestradiol with drospirenone and folate, which could potentially reduce the risk of neural tube defects if pregnancy occurs[5].

It’s crucial to discuss your medical history, lifestyle, and any concerns with your healthcare provider when considering ethinylestradiol-containing contraceptives. They can help determine the most appropriate formulation and dosage for your individual needs.

Aspect Details
Main Focus Safety and efficacy of oral contraceptives containing ethinylestradiol
Study Designs Randomized, open-label, crossover, observational
Administration Methods Oral tablets, transdermal patches
Combination Drugs Levonorgestrel, gestodene, drospirenone, CP-690,550, BI 201335, NNC0194-0499
Primary Outcomes Pregnancy prevention, ovulation inhibition, drug pharmacokinetics
Secondary Outcomes Hormone level changes, follicle size, endometrial thickness, adverse events
Special Considerations Drug interactions, folate supplementation, effects on homocysteine levels

FAQ

  • What is ethinylestradiol? Ethinylestradiol is a synthetic form of estrogen commonly used in oral contraceptives. It is often combined with progestins to create effective birth control pills.
  • What are the main purposes of the clinical trials involving ethinylestradiol? The clinical trials aim to investigate the safety and efficacy of oral contraceptives containing ethinylestradiol, their ability to inhibit ovulation, potential drug interactions, and effects on hormone levels and metabolism.
  • How is ethinylestradiol administered in these trials? Ethinylestradiol is administered in various forms, including oral tablets and transdermal patches. The dosage and administration method vary depending on the specific trial and contraceptive formulation being studied.
  • What are some of the other drugs or compounds studied alongside ethinylestradiol? Other drugs or compounds studied alongside ethinylestradiol include progestins like levonorgestrel, gestodene, and drospirenone, as well as investigational drugs like CP-690,550, BI 201335, and NNC0194-0499.
  • What are some of the outcomes measured in these clinical trials? Outcomes measured include pregnancy prevention, ovulation inhibition, changes in hormone levels, drug pharmacokinetics (how the body processes the drug), and potential side effects or adverse events.

Ongoing Clinical Trials on Ethinylestradiol

  • Study on the Effects of Ethinylestradiol, Levonorgestrel, and Chlormadinone Acetate in Hormonal Contraception for Women Using Oral Contraceptives

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria

  • A study comparing the effects of estetrol and drospirenone, ethinylestradiol and drospirenone, and drospirenone in women with polycystic ovary syndrome (PCOS)

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Finland

  • Contraception study in women: comparing oral drospirenone‑only, drospirenone + ethinylestradiol, and drospirenone + estetrol tablets

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Finland

  • Study of cabergoline compared to dienogest and ethinylestradiol for reducing endometriosis symptoms and lesion size in women with confirmed endometriosis

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Menstrual Bleeding and Tolerability of Norgestimate and Ethinylestradiol for Women Using Contraceptives in Italy

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Italy

  • Study on Ethinylestradiol/Levonorgestrel and Vitamin E for Treating Menstrual and Perimenopausal Migraines in Women

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Effect of iclepertin on the blood levels of ethinylestradiol and levonorgestrel in healthy premenopausal women

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany

  • Study on the Effects of Hormonal Contraceptives on the Brain: Comparing Drospirenone and Estetrol with Ethinylestradiol and Levonorgestrel in Women Using Contraception

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Sweden

  • Study of Darovasertib for Patients with Localized Uveal Melanoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands

Glossary

  • Ethinylestradiol (EE): A synthetic form of estrogen commonly used in oral contraceptives.
  • Pharmacokinetics: The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Ovulation inhibition: The prevention of the release of an egg from the ovary, which is one of the primary mechanisms of action for oral contraceptives.
  • Progestin: A synthetic form of progesterone, often combined with estrogen in oral contraceptives.
  • Transdermal patch: A method of delivering medication through the skin and into the bloodstream.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, used in pharmacokinetic studies.
  • Cmax: The maximum concentration of a drug in the blood after administration.
  • Steady state: The condition where the overall intake of a drug is in dynamic equilibrium with its elimination.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Folate: A B vitamin that is important for cell growth and metabolism, often added to some oral contraceptives to reduce the risk of neural tube defects.

References

  1. https://clinicaltrials.gov/study/NCT01137708
  2. https://clinicaltrials.gov/study/NCT00915915
  3. https://clinicaltrials.gov/study/NCT02652650
  4. https://clinicaltrials.gov/study/NCT01570244
  5. https://clinicaltrials.gov/study/NCT00468481